Combination extends OS in metastatic colorectal cancer

The addition of bevacizumab to trifluridine and tipiracil extended OS among patients with advanced colorectal cancer, according to a topline data announcement.Trifluridine and tipiracil (Lonsurf; Taiho Oncology, Servier) is an oral agent that utilizes a dual mechanism of action to maintain clinical activity. Trifluridine, an antineoplastic nucleoside analogue, interferes with DNA function. The blood concentration of trifluridine is maintained via tipiracil, an inhibitor of the trifluridine-degrading enzyme thymidine phosphorylase.The randomized phase 3 SUNLIGHT trial included 492 patientsRead More

Related Articles